Number of participants with any adverse event (primary tolerability outcome) · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…
Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: adverse events ‐ at least 1 adverse event compared with topical betamethasone dipropionate (moderate certainty).
1 finding from 1 review
Secondary: investigator‐rated reduction in severity ‐ DASIb · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…
1 finding from 1 review
Oral ulcers (number, size, healing time) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Ergun 1997 (cyclosporin A in orabase vs placebo orabase, 24 patients; high risk of reporting bias): no data were presented; authors reported no clinical improvement in the number, size, and healing time of ulcers for…
1 study · 24 participants
GRADE not reported
Alleviation of oral aphthous ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Cyclosporin (systemic; 10 mg/kg/day for 16 weeks) led to higher alleviation of oral aphthous ulcers compared with colchicine (systemic; 1 mg daily); GRADE not reported.
1 finding from 1 review
Episode frequency associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
SoF (topical interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim): "5 placebo-controlled trials evaluated topical interventions (sucralfate suspension (2 trials), interferon-alpha (2…
Studies not reported
GRADE not reported
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
SoF (topical interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim): "5 placebo-controlled trials evaluated topical interventions (sucralfate suspension (2 trials), interferon-alpha (2…
Studies not reported
GRADE not reported
Pain associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
SoF (topical interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim): "5 placebo-controlled trials evaluated topical interventions (sucralfate suspension (2 trials), interferon-alpha (2…
Studies not reported
GRADE not reported
Episode duration associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
SoF (topical interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim): "5 placebo-controlled trials evaluated topical interventions (sucralfate suspension (2 trials), interferon-alpha (2…
Studies not reported
GRADE not reported
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
It is very uncertain whether summary of findings table ‐ Oral classical immunosuppressants… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (very low certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
Health‐related quality of life (AQoL‐8D) · adults with alopecia areata
1 finding from 1 review
Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Prevalence and severity of oral and TMJ diseases/conditions (periodontal status and dental caries) · Children and adolescents with juvenile idiopathic arthritis (JIA)
Some studies suggested greater JIA disease activity/severity (and certain medications) was associated with worse periodontal and caries outcomes, but small samples meant no solid conclusion could be drawn (ungraded).
1 finding from 1 review
Intervention not reported
Cyclosporin A (2 RCTs; 49 participants) · patients with moderate to severe eczema
It is very uncertain whether the intervention changes cyclosporin A (2 RCTs; 49 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Cyclosporin A (3 RCTs; 74 participants) · patients with moderate to severe eczema
It is very uncertain whether the intervention changes cyclosporin A (3 RCTs; 74 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Cyclosporine A · people undergoing liver transplantation
It is very uncertain whether the intervention changes cyclosporine A (very low certainty).
1 finding from 1 review
Intervention not reported
Cyclosporine A plus azathioprine · people undergoing liver transplantation
It is very uncertain whether the intervention changes cyclosporine A plus azathioprine (very low certainty).
1 finding from 1 review
Intervention not reported
Cyclosporine A plus azathioprine plus glucocorticosteroids · people undergoing liver transplantation
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Cyclosporine A plus glucocorticosteroids · people undergoing liver transplantation
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Cyclosporine A plus mycophenolate plus glucocorticosteroids · people undergoing liver transplantation
1 finding from 1 review
no estimate extracted
Studies not reported
Very low